Read the full deal writeup
Sign up for a free Accredited account to read the editorial writeup, financials, and broker contact for this deal.


Full Editorial Writeup
Central South Carolina Pharmacy is an independent retail pharmacy doing roughly $18.1M in annual revenue with $778K in EBITDA. The business is fully staffed with pharmacists and support personnel, and the listing explicitly markets it as absentee-operable, meaning the owner is not the primary pharmacist or day-to-day operator. For a buyer, that combination of scale and an existing team is attractive because it de-risks the transition and does not require the buyer to hold a pharmacist license personally.
The core business is dispensing prescription medications, which is about as non-discretionary as retail gets. Patients on maintenance medications for chronic conditions refill month after month, which creates a sticky, repeat-revenue base that is far more durable than typical retail foot traffic. The margin profile is thin on a percentage basis (EBITDA margin around 4.3% on $18M of revenue), which is characteristic of pharmacy economics where reimbursement rates and wholesale drug costs compress the spread.
At a $2.75M ask against $778K EBITDA, the deal prices at about 3.53x, which sits in a reasonable band for an independent pharmacy. The key question for any buyer is whether that revenue and margin are reimbursement-stable, because pharmacy profitability lives and dies on payer mix, PBM contracts, and DIR fee dynamics that can swing earnings without any change in prescription volume.
- Two-Location Independent Retail Pharmacy, Southern California
- Medicare & Medicaid-Certified Home Healthcare Agency, Franklin County Ohio
- Northwest Ohio Skilled Home Health Agency, Joint Commission Accredited
- Two-Location Independent Pharmacy, Orange County & San Bernardino, CA
- DME & Medical Supply Business, 25-Year Los Angeles County Operator
- Multi-Location Therapy Practice, Denver Manager-Run Healthcare Group
Want the full analysis on every deal? to screen live listings and read our operator-level writeups.
